MS News

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at some of what’s been happening: A good report for Vumerity Final results are in from the EVOLVE-MS-1 clinical trial for patients with…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at some of what’s been happening. MS relapses and COVID-19 Since COVID-19 became a concern over three years ago, I’ve read many comments…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: ATA188 fails a big test ATA188 is an experimental cell therapy developed by Atara Biotherapeutics aimed at easing MS…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Lemtrada or stem cell transplant? While the U.S. Food and Drug Administration has not yet approved stem cell transplants…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Dalfampridine side effects The side effects that might occur if you use dalfampridine (sold under the brand name Ampyra)…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. This week, the stories cover research presented at the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. This week, the stories cover research presented at the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: ‘Silent’ MS progression Readers of the MS News Today website and Facebook page sometimes wonder why their MS…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Stem cell transplant found to be safe, effective in recent study Autologous hematopoietic stem cell transplant (aHSCT) has been…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: An ‘inverse vaccine’ trial to treat MS What’s an “inverse vaccine,” you might ask? While traditional vaccines rev up…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Vaccines pose no unusual risk of MS hospitalization, study says It’s time for me to get my seasonal flu shot,…

Note: This column was updated Sept. 12, 2023, to correct that Octave’s MSDA blood test is currently available and in use throughout the U.S. Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: PPMS is difficult to diagnose, report says Most people who have multiple sclerosis start out with a diagnosis of…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Can noninvasive brain stimulation reduce MS spasticity? For a long time, I’ve had to deal with spasticity, a common…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: MS is costly to patients and society People with MS understand how costly the disease can be in terms of…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Is it MS or something else? Should all autoimmune diseases that damage myelin be called MS? Probably not, according…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Neurologists comment on DMTs available for RRMS There are 20 disease-modifying therapies (DMTs) available to treat MS in the…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Could MS be predicted by an artificial intelligence tool? Wouldn’t it be great if there was a way to predict…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Are DMTs useful and safe for older MS patients? The MS News Today story “Can elderly MS patients…

Editor’s note: “MS News Notes” will return to its regular Monday morning schedule next week. Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: A 10-minute injection of…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Testing a new MRI contrast agent One concern that some people with MS have when getting an MRI…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Another study shows positive results with stem cell therapy Yet another study has concluded that autologous hematopoietic…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: MS experts offer more than 50 vaccine guidelines I know there are different opinions about vaccines, and I’ve…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Myelin repair and clemastine The Multiple Sclerosis News Today story “MRI method detects myelin repair with…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Foralumab shows early positive results for SPMS I’ll say up front that this is a very small study.

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Is CD40L a better way to control MS inflammation? CD40L is a protein that’s involved with activation of…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: A closer look at the EBV-MS link Much has been written over the past few years about the…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Early stem cell transplants I’ve read the headline “Stem cell therapy may do most good when given…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Surgical treatment of facial pain I’ve never heard of surgery being used as an MS treatment, but…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Study: Starting Ocrevus early is better than later The MS News Today story “AAN 2023: Early…